The T-VAD regimen was also more effective for reducing serum VEGF in initial MM than recurrent MM, even when treatment was curative in both groups (MD = -120.20, [-164.60–-39.80], P<0.01) (Figure 6). This evidence concerns the gene VEGFA and Miyoshi myopathy.